報價延遲最少15分鐘:2026/04/25 05:36 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.08 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.59/1.00
|
|
企業價值
14.48B
|
| 資產負債 |
|
每股賬面淨值
9.13
|
| 現金流量 |
|
現金流量率
0.23
|
| 損益表 |
|
收益
7.52B
|
|
每股收益
10.16
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses onproducts derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products. |
